Enquyst Technologies

What Enquyst Technologies does

Enquyst Technologies is a private biotechnology company founded in 2017 in Lowell, Massachusetts by Dr. Jason Criscione, developing the patented Isoelectric Point Purification (IPP) technology — a flow-through, chromatography-free downstream purification platform for biologics manufacturing. IPP separates target biomolecules using chemistry, physics, and fluid dynamics, exploiting isoelectric point, charge heterogeneity, and molecular size rather than surface interactions with resins. The technology is positioned to replace Protein A, CEX, and AEX chromatography unit operations in bioprocess workflows, with documented case-study outcomes of 44% downstream COGS reduction, 12% yield improvement, and 36% reduction in single-use media bags in a 150 kg/yr fed-batch mAb scenario. The product platform extends across application areas including monoclonal antibodies, bispecific antibodies, ADCs, viral vectors, mRNA/LNPs, viruses, plasmid DNA, and peptides, and integrates in-line process analytical technologies and disposable sterile fluid paths to support continuous manufacturing.

The company operates an enterprise B2B go-to-market selling bioprocess equipment directly to biopharmaceutical manufacturers through field sales, industry conferences (BIO, Bioprocess International, Biotech Showcase, Interphex, NIIMBL National Meetings), and strategic co-development partnerships with Lonza Biologics, MilliporeSigma, and UMass Lowell under NIIMBL Project Call 7.1. Capital structure includes a $3 million NJ Innovation Evergreen Fund equity investment (July 2025) led by Eckuity Capital, a $10.5 million Gates Foundation Grand Challenge award (October 2025) routed through NIIMBL, and an NIIMBL grant from April 2024. Operations comprise a 1-10 person team across R&D facilities in Lowell, MA (headquarters) and North Brunswick, NJ (NJ Bioscience Center, opened August 2025). The leadership team combines founder/CSO Dr. Jason Criscione (PhD, Yale), COO Karim Massarani (ex-Merck/MSD, Becton Dickinson, Amzak Health), VP Engineering Ali Ersen (PhD, UCSD), and Director of Hardware Engineering Brock Jacobites. Pricing is quote-based enterprise equipment sales; revenue is not yet disclosed.

Name

Enquyst Technologies

Legal name

Enquyst Technologies

Website

https://enquyst.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Enquyst Technologies develops patented Isoelectric Point Purification (IPP) technology, a chromatography-free flow-through platform for downstream purification of biologics, sold as bioprocess equipment to biopharmaceutical manufacturers producing monoclonal antibodies, viral vectors, mRNA, and other therapeutic modalities.

Ownership category

akta.pro rank

Product category

Bioprocess Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Downstream Processing & Purification Technologies (chromatography, filtration, centrifugation) (HLAAAJAB)

akta.pro secondary industries

Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC), Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring) (HLAAAJAD), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

Keywords

• Bioprocess equipment
• Downstream processing
• Biologics purification
• Monoclonal antibody manufacturing
• Chromatography-free purification

Headquarters

HQ city

Lowell

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Bioprocess Equipment Sales: Sale of IPP technology equipment and systems to biopharmaceutical manufacturers for downstream processing of biologics. Equipment designed for continuous manufacturing with ultra-high purity purification capabilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Enquyst Technologies designs, develops, and sells bioprocess equipment based on its patented Isoelectric Point Purification (IPP) Technology Platform for downstream processing of biologics. The chromatography-free, flow-through system isolates and purifies target biomolecules such as monoclonal antibodies, bispecific antibodies, ADCs, viral vectors, mRNA, plasmid DNA, peptides, and viruses using chemistry, physics, and fluid dynamics. Integrated in-line process analytical technologies, disposable sterile fluid paths, and a modular design enable truly continuous manufacturing with reduced downstream processing costs for biopharmaceutical manufacturers.

Product overview

Enquyst Technologies offers the Isoelectric Point Purification (IPP) Technology Platform as its core product, a disruptive, chromatography-free downstream processing solution for biologics manufacturing. The platform integrates the IPP technology with in-line process analytical technologies to enable truly continuous manufacturing. The system is designed as a modular solution applicable across diverse biological product types including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, viral vectors, mRNA and lipid nanoparticles, viruses, plasmid DNA, and peptides. The technology replaces traditional chromatography unit operations (Protein A, CEX, AEX) with a flow-through purification approach using only chemistry, physics, and fluid dynamics.

Differentiator

Problem solved

Functional benefit

Brands

• IPP Technology: Isoelectric Point Purification technology - a patented flow-through purification technology that separates without relying on a target biomolecule's interaction with a surface, matrix, or resin

Products and services

• Isoelectric Point Purification (IPP) Technology Platform A patented, chromatography-free, flow-through purification platform sold as bioprocess equipment to biopharmaceutical manufacturers. The platform isolates and purifies target biomolecules (including monoclonal antibodies, bispecific antibodies, ADCs, viral vectors, mRNA and lipid nanoparticles, viruses, plasmid DNA, and peptides) using chemistry, physics, and fluid dynamics, exploiting isoelectric point, charge heterogeneity, and molecular size rather than surface interactions with resins. It enables truly continuous manufacturing with integrated in-line process analytical technologies, disposable sterile fluid paths, and a modular design.

Quantifiable outcome

• 44% reduction in total COGS for downstream processing (DSP) in fed-batch mAb production case study
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Gates FoundationcoreStrategic or Co-development Partner · 1 October 2025NIIMBL-led team selected for Gates Grand Challenge $10.5M funding award to develop low-cost monoclonal antibody manufacturing technologies. Enquyst is a key partner using funding to scale-up its IPP technology targeting $10 per gram production cost goal.
• NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals)coreStrategic or Co-development Partner · 1 April 2024Enquyst awarded NIIMBL grant for Project Call 7.1: Technologies for intensified processing of therapeutic proteins. Collaboration with UMass Lowell and corporate sponsors Lonza Biologics and MilliporeSigma to advance IPP technology development.
• Lonza BiologicscoreStrategic or Co-development PartnerCorporate sponsor collaborating with Enquyst Technologies and MilliporeSigma as part of NIIMBL Project Call 7.1 grant for intensified processing of therapeutic proteins.
• MilliporeSigmacoreStrategic or Co-development PartnerCorporate sponsor collaborating with Enquyst Technologies and Lonza Biologics as part of NIIMBL Project Call 7.1 grant for intensified processing of therapeutic proteins.
• UMass LowellcoreStrategic or Co-development PartnerAcademic partner collaborating with Enquyst Technologies on NIIMBL Project Call 7.1 for technologies for intensified processing of therapeutic proteins.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cytiva: Cytiva (a Danaher company) is the global leader in bioprocess chromatography resins, columns, and downstream processing equipment. It is the dominant incumbent whose Protein A and ion-exchange platforms Enquyst aims to disrupt, and a critical benchmark for the addressable market.
• Sartorius AG: Sartorius is a major bioprocess equipment and consumables supplier covering upstream and downstream processing for biologics manufacturers. It competes broadly with Enquyst in the bioprocess equipment category, with deep relationships across CDMOs and large biopharma.
• Thermo Fisher Scientific: Thermo Fisher's bioproduction and chromatography & mass spectrometry divisions supply end-to-end bioprocess and analytical solutions to biologics manufacturers. It competes broadly with Enquyst across bioprocess equipment, consumables, and analytics.

Direct peers

• MilliporeSigma: MilliporeSigma (the life science arm of Merck KGaA) supplies chromatography resins, filtration, and single-use bioprocess solutions. It is both a direct competitor in DSP and an existing Enquyst collaborator/corporate sponsor through the NIIMBL grant.
• Tosoh Bioscience: Tosoh Bioscience is a leading supplier of chromatography resins (including Protein A and ion exchange) and HPLC columns for bioprocess purification. It directly competes with Enquyst's IPP in the downstream capture and polishing steps the company targets.
• Bio-Rad Laboratories: Bio-Rad is a major supplier of chromatography media, process-scale columns, and bioprocess analytics for biologics manufacturing. Its process chromatography product line directly overlaps the unit operations Enquyst's IPP is designed to replace.
• Repligen Corporation: Repligen specializes in bioprocess products for biologics manufacturing, including chromatography alternatives (e.g., OPUS pre-packed columns, alternating tangential flow filtration) that compete with traditional Protein A workflows. Repligen is a close comparable in offering innovative DSP solutions to biomanufacturers.
• 3M (Separation and Purification Sciences, now Solventum): 3M's Separation and Purification Sciences business (spun off as Solventum) developed novel membrane and adsorbent technologies for bioprocess clarification and purification. It is a direct peer in offering non-chromatography alternatives to biomanufacturers.

Emerging players

• Astrea Bioseparations: Astrea Bioseparations is a smaller, niche-focused developer of next-generation chromatography and purification technologies for biologics. As a focused emerging player pursuing novel DSP approaches, it is comparable in scale and category focus to Enquyst.
• Purilogics (a Repligen company): Purilogics developed hydrogel-based membrane chromatography products for mAb and biologic purification prior to its acquisition by Repligen. It is a relevant comparable as an emerging technology focused on chromatography alternatives in bioprocess DSP.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/enquyst-technologies-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enquyst Technologies